Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype

Matrix Biology

Volumn 55, Issue , 2016, Pages 22-34

  Ramani, Vishnu C ^a,b   Vlodavsky, Israel ^c   Ng, Mary ^d   Zhang, Yi ^d   Barbieri, Paola ^e   Noseda, Alessandro ^e   Sanderson, Ralph D ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d ELI LILLY AND COMPANY   (United States)

^e Sigma Tau Research Switzerland   (Switzerland)

Author keywords

Chemotherapy; Heparanase; Multiple myeloma; NF B; Proteasome inhibitors; Roneparstat

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; ACETYLCYSTEINE; BORTEZOMIB; CARFILZOMIB; CELL EXTRACT; CYCLOHEXIMIDE; DEXAMETHASONE; DOXORUBICIN; GELATINASE B; GLYCOSAMINOGLYCAN; HEPARANASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RONEPARSTAT; SCATTER FACTOR; SYNDECAN 1; TUMOR NECROSIS FACTOR; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; OLIGOPEPTIDE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CELL ACTIVATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; MYELOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BORTEZOMIB; CELL LINE, TUMOR; DOXORUBICIN; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HUMANS; MELANOMA; MELPHALAN; OLIGOPEPTIDES; PHENOTYPE;

EID: 84961911829     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.03.006     Document Type: Article

References (45)

1. [1] Barash, U., Cohen-Kaplan, V., Dowek, I., Sanderson, R.D., Ilan, N., Vlodavsky, I., Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 277 (2010), 3890–3903.
2. [2] Ramani, V.C., Purushothaman, A., Stewart, M.D., Thompson, C.A., Vlodavsky, I., Au, J.L., Sanderson, R.D., The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 280 (2013), 2294–2306.
3. [3] Iozzo, R.V., Sanderson, R.D., Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 15 (2011), 1013–1031.
4. [4] Theocharis, A.D., Skandalis, S.S., Neill, T., Multhaupt, H.A., Hubo, M., Frey, H., Gopal, S., Gomes, A., Afratis, N., Lim, H.C., Couchman, J.R., Filmus, J., Sanderson, R.D., Schaefer, L., Iozzo, R.V., Karamanos, N.K., Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim. Biophys. Acta, Rev. Cancer 1855 (2015), 276–300.
5. [5] Iozzo, R.V., Schaefer, L., Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 42 (2015), 11–55.
6. [6] Ramani, V.C., Yang, Y., Ren, Y., Nan, L., Sanderson, R.D., Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J. Biol. Chem. 286 (2011), 6490–6499.
7. [7] Yang, Y., Macleod, V., Bendre, M., Huang, Y., Theus, A.M., Miao, H.Q., Kussie, P., Yaccoby, S., Epstein, J., Suva, L.J., Kelly, T., Sanderson, R.D., Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105 (2005), 1303–1309.
8. [8] Purushothaman, A., Chen, L., Yang, Y., Sanderson, R.D., Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 283 (2008), 32628–32636.
9. [9] Kelly, T., Miao, H.Q., Yang, Y., Navarro, E., Kussie, P., Huang, Y., MacLeod, V., Casciano, J., Joseph, L., Zhan, F., Zangari, M., Barlogie, B., Shaughnessy, J., Sanderson, R.D., High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 63 (2003), 8749–8756.
10. [10] Barash, U., Zohar, Y., Wildbaum, G., Beider, K., Nagler, A., Karin, N., Ilan, N., Vlodavsky, I., Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia 28 (2014), 2178–2187.
11. [11] Sanderson, R.D., Iozzo, R.V., Targeting heparanase for cancer therapy at the tumor-matrix interface. Matrix Biol. 31 (2012), 283–284.
12. [12] Jung, O., Trapp-Stamborski, V., Purushothaman, A., Jin, H., Wang, H., Sanderson, R.D., Rapraeger, A.C., Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis, 5, 2016, e202.
13. [13] DeVita, V.T. Jr., Chu, E., A history of cancer chemotherapy. Cancer Res. 68 (2008), 8643–8653.
14. [14] Bruchard, M., Mignot, G., Derangere, V., Chalmin, F., Chevriaux, A., Vegran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J.L., Kanellopoulos, J., Martin, F., Rebe, C., Apetoh, L., Ghiringhelli, F., Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19 (2013), 57–64.
15. [15] Sun, Y., Campisi, J., Higano, C., Beer, T.M., Porter, P., Coleman, I., True, L., Nelson, P.S., Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18 (2012), 1359–1368.
16. [16] Ramani, V.C., Sanderson, R.D., Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol. 35 (2014), 215–222.
17. [17] Ramani, V.C., Zhan, F., He, J., Barbieri, P., Noseda, A., Tricot, G., Sanderson, R.D., Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget 7 (2015), 1598–1607.
18. [18] Futscher, B.W., Foley, N.E., Gleason-Guzman, M.C., Meltzer, P.S., Sullivan, D.M., Dalton, W.S., Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int. J. Cancer 66 (1996), 520–525.
19. [19] Bellamy, W.T., Dalton, W.S., Gleason, M.C., Grogan, T.M., Trent, J.M., Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 51 (1991), 995–1002.
20. [20] Yang, Y., Macleod, V., Miao, H.Q., Theus, A., Zhan, F., Shaughnessy, J.D. Jr., Sawyer, J., Li, J.P., Zcharia, E., Vlodavsky, I., Sanderson, R.D., Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 282 (2007), 13326–13333.
21. [21] Wu, W., Pan, C., Meng, K., Zhao, L., Du, L., Liu, Q., Lin, R., Hypoxia activates heparanase expression in an NF-kappaB dependent manner. Oncol. Rep. 23 (2010), 255–261.
22. [22] Cao, H.J., Fang, Y., Zhang, X., Chen, W.J., Zhou, W.P., Wang, H., Wang, L.B., Wu, J.M., Tumor metastasis and the reciprocal regulation of heparanase gene expression by nuclear factor kappa B in human gastric carcinoma tissue. World J. Gastroenterol. 11 (2005), 903–907.
23. [23] Hadigal, S.R., Agelidis, A.M., Karasneh, G.A., Antoine, T.E., Yakoub, A.M., Ramani, V.C., Djalilian, A.R., Sanderson, R.D., Shukla, D., Heparanase is a host enzyme required for herpes simplex virus-1 release from cells. Nat. Commun., 6, 2015, 6985.
24. [24] Dolcet, X., Llobet, D., Encinas, M., Pallares, J., Cabero, A., Schoenenberger, J.A., Comella, J.X., Matias-Guiu, X., Proteasome inhibitors induce death but activate NF-kappa B on endometrial carcinoma cell lines and primary culture explants. J. Biol. Chem. 281 (2006), 22118–22130.
25. [25] Nemeth, Z.H., Wong, H.R., Odoms, K., Deitch, E.A., Szabo, C., Vizi, E.S., Hasko, G., Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells. Mol. Pharmacol. 65 (2004), 342–349.
26. [26] Li, C., Chen, S., Yue, P., Deng, X., Lonial, S., Khuri, F.R., Sun, S.Y., Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent Ikappa B (alpha) degradation. J. Biol. Chem. 285 (2010), 16096–16104.
27. [27] Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N.C., Richardson, P.G., Carrasco, R.D., Anderson, K.C., Bortezomib induces canonical nuclear factor-kappa B activation in multiple myeloma cells. Blood 114 (2009), 1046–1052.
28. [28] Yarde, D.N., Oliveira, V., Mathews, L., Wang, X., Villagra, A., Boulware, D., Shain, K.H., Hazlehurst, L.A., Alsina, M., Chen, D.T., Beg, A.A., Dalton, W.S., Targeting the fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 69 (2009), 9367–9375.
29. [29] Vreys, V., Delande, N., Zhang, Z., Coomans, C., Roebroek, A., Durr, J., David, G., Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J. Biol. Chem. 280 (2005), 33141–33148.
30. [30] Gingis-Velitski, S., Zetser, A., Kaplan, V., Ben-Zaken, O., Cohen, E., Levy-Adam, F., Bashenko, Y., Flugelman, M.Y., Vlodavsky, I., Ilan, N., Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J. Biol. Chem. 279 (2004), 44084–44092.
31. [31] Blich, M., Golan, A., Arvatz, G., Sebbag, A., Shafat, I., Sabo, E., Cohen-Kaplan, V., Petcherski, S., Avniel-Polak, S., Eitan, A., Hammerman, H., Aronson, D., Axelman, E., Ilan, N., Nussbaum, G., Vlodavsky, I., Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler. Thromb. Vasc. Biol. 33 (2013), e56–e65.
32. [32] Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., Anderson, K.C., The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20 (2001), 4519–4527.
33. [33] Purushothaman, A., Uyama, T., Kobayashi, F., Yamada, S., Sugahara, K., Rapraeger, A.C., Sanderson, R.D., Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115 (2010), 2449–2457.
34. [34] Fux, L., Ilan, N., Sanderson, R.D., Vlodavsky, I., Heparanase: busy at the cell surface. Trends Biochem. Sci. 34 (2009), 511–519.
35. [35] Meirovitz, A., Hermano, E., Lerner, I., Zcharia, E., Pisano, C., Peretz, T., Elkin, M., Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res. 71 (2011), 2772–2780.
36. [36] Ogishima, T., Shiina, H., Breault, J.E., Tabatabai, L., Bassett, W.W., Enokida, H., Li, L.C., Kawakami, T., Urakami, S., Ribeiro-Filho, L.A., Terashima, M., Fujime, M., Igawa, M., Dahiya, R., Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin. Cancer Res. 11 (2005), 1028–1036.
37. [37] Ostrovsky, O., Shimoni, A., Baryakh, P., Morgulis, Y., Mayorov, M., Beider, K., Shteingauz, A., Ilan, N., Vlodavsky, I., Nagler, A., Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. J. Leukoc. Biol. 95 (2014), 677–688.
38. [38] Andela, V.B., Schwarz, E.M., Puzas, J.E., O'Keefe, R.J., Rosier, R.N., Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res. 60 (2000), 6557–6562.
39. [39] Demchenko, Y.N., Kuehl, W.M., A critical role for the NFκB pathway in multiple myeloma. Oncotarget 1 (2010), 59–68.
40. [40] Demchenko, Y.N., Glebov, O.K., Zingone, A., Keats, J.J., Bergsagel, P.L., Kuehl, W.M., Classical and/or alternative NF-kappa B pathway activation in multiple myeloma. Blood 115 (2010), 3541–3552.
41. [41] Yang, Y., Ren, Y., Ramani, V.C., Nan, L., Suva, L.J., Sanderson, R.D., Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res. 70 (2010), 8329–8338.
42. [42] Bayer-Garner, I.B., Sanderson, R.D., Dhodapkar, M.V., Owens, R.B., Wilson, C.S., Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod. Pathol. 14 (2001), 1052–1058.
43. [43] Zhang, L., Ngo, J.A., Wetzel, M.D., Marchetti, D., Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia 17 (2015), 101–113.
44. [44] Ramani, V.C., Pruett, P.S., Thompson, C.A., DeLucas, L.D., Sanderson, R.D., Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J. Biol. Chem. 287 (2012), 9952–9961.
45. [45] Weissmann, M., Arvatz, G., Horowitz, N., Feld, S., Naroditsky, I., Zhang, Y., Ng, M., Hammond, E., Nevo, E., Vlodavsky, I., Ilan, N., Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 704–709.